Navigation Links
Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
Date:8/24/2010

help to address the lack of novel antimicrobial compounds in the pipeline that is a growing problem in the face of rapidly emerging multidrug-resistant organisms.

The MCMSI would display a higher-risk tolerance than currently exists by the US government for these products and accept a longer time horizon.  The fund would operate independently and outside the government as a 501(c)(3) corporation or other similar alternative. In addition to its own investments, the MCMSI would leverage private capital, provide expert consultation, and link promising companies with potential partners in the private sector.  Secretary of HHS Kathleen Sebelius noted that the MCMSI enterprise is part of a new $1.9 billion effort to ensure the U.S. has a "nimble" and "flexible" system to produce drugs and vaccines against any national medical emergency, whether from a terrorist attack or natural disaster.

To view a full copy of the report, please visit:

https://www.medicalcountermeasures.gov/documents/MCMReviewFinalcover-508.pdf

About Restanza

Restanza is a novel oral once-a-day antibiotic that is in late stage development for the treatment of community acquired bacterial pneumonia (CABP) and biodefense pathogens including anthrax, plague and tularemia. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria including CA-MRSA and pathogens associated with respiratory tract infections and appears to be effective against penicillin-, macrolide- and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CABP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... NEW YORK , July 25, 2014  Smile ... selected to showcase their Virtual Surgery Simulator among ... 2014, which will take place in Washington, ... for the Performing Arts. "Smile Train ... BioDigital alongside the talented community of innovators in health ...
(Date:7/25/2014)... GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to announce the ... LLC, an Illinois limited liability company ... medical marijuana licenses in the state of Illinois ... 20% equity interest in LaurelCo, LLC in exchange for licenses ... well as all technology related to the machines and to ...
(Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... for the third quarter of 2009, which includes a ... primarily from strong cash collections related to prior period ... of $32.1 million for the comparable period in 2008, ...
... (Nasdaq: ROCM ) today announced operating results for its ... Company reported sales of $9,009,000 for the current quarter compared ... The Company reported a quarterly net loss of $229,000 or ... or $.03 per diluted share for the fourth quarter of ...
Cached Medicine Technology:Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 3Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 4Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 7Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 8Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 9Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 10Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 12
(Date:7/26/2014)... “Healthy teeth are important, and having your teeth cleaned regularly ... Health Center of Snohomish County (CHC) in their article, “ ... integration of medical and dental care is the best way ... encourage regular cleanings and checkups not only with a family ... adults will find knowledgeable and friendly staff that ...
(Date:7/26/2014)... The U.S. Food & Drug Administration (FDA) has ... medication guide for AndroGel to include blood clots in the ... topical low testosterone medication, notes Wright & Schulte LLC. ... the low testosterone theapy drug, has also updated the official ... as signs of a blood clot in the leg and ...
(Date:7/26/2014)... 2014 According to the Banish My ... a comprehensive guide that covers detailed instructions on how ... the need of any medication. , Vkool reveals ... and safe remedies for relieving symptoms of keratosis pilaris ...     How to treat children's keratosis pilaris ...
(Date:7/25/2014)... Staffordshire, UK (PRWEB) July 26, 2014 ... a variety of dental services including general dentistry, clear ... practice opening in September this year in Derby. The ... is at the HollyBrook Medical Centre in Littleover, Derby. ... the new practice. , The new dental practice, which ...
(Date:7/25/2014)... Angeles, CA (PRWEB) July 25, 2014 In ... talk about, and eager to reverse the symptoms associated with ... in the media at large, a new case study ... real benefits of testosterone therapy using bioidentical hormones. ... a 38-year-old father from Seattle who found himself beginning to ...
Breaking Medicine News(10 mins):Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3
... The Turning Point Group, LP announces,the appointment of ... Healthcare Division. As Vice President of Client Services, Haney,will ... base of The,Turning Point Group, the Award Winning Customer ... A&M MBA, is a Customer Experience expert with over,25 ...
... New Book Royalties to Benefit TAC, ... The Insanity Offense,( http://www.amazon.com/Insanity-Offense-Americas-Seriously-Endangers/dp/039 ,3066584/ref=pd_bbs_sr_1?ie=UTF8&s=books&qid=1213968063&sr=8-1 ), ... in detail one of the greatest ... the past five decades, hundreds,of thousands ...
... confirm what many patients, doctors suspected , , MONDAY, June ... to put patients to sleep during surgery -- can ... according to Georgetown University Medical Center researchers. , This ... lead to increased use of general anesthetics that do ...
... at The University of Texas at Austin is ... the average person to donate idle computer time ... Muhammad Zaman, assistant professor in biomedical engineering, recently ... CELS@Home for short ( http://cels-at-home-dev.dyndns.org/cels/ ). The program ...
... Consumer,Watchdog warned today that a new bill to be ... to recover unpaid medical bills resulting from,cancellations of coverage, ... and recent settlements with regulators are,part of an industry ... guise of reform., AB 1945 by Assemblyman Hector ...
... MEETING, Pa., June 23 /Xinhua-PRNewswire/ -- BMP Sunstone,Corporation ... announced,that the Company will present at the following ... held in London. Management is,currently scheduled to present ... time and,hold one-on-one meetings the same day at ...
Cached Medicine News:Health News:Dr. Torrey Takes 'The Insanity Offense' 2Health News:General Anesthesia Boosts Post-Op Pain 2Health News:Idle computers offer hope to solve cancer's mysteries through grid computing project 2Health News:CA Legislature's 'Reform' of Health Insurance Cancellations Resembles Insurance Industry's Own Plan; Insurers, Satisfied With Getting a Legal Edge Against Patients, Drop Opposition to the Bill 2Health News:CA Legislature's 'Reform' of Health Insurance Cancellations Resembles Insurance Industry's Own Plan; Insurers, Satisfied With Getting a Legal Edge Against Patients, Drop Opposition to the Bill 3Health News:CA Legislature's 'Reform' of Health Insurance Cancellations Resembles Insurance Industry's Own Plan; Insurers, Satisfied With Getting a Legal Edge Against Patients, Drop Opposition to the Bill 4Health News:CA Legislature's 'Reform' of Health Insurance Cancellations Resembles Insurance Industry's Own Plan; Insurers, Satisfied With Getting a Legal Edge Against Patients, Drop Opposition to the Bill 5Health News:BMP Sunstone Announces Participation in June Investor Conferences 2
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... expanded memory capabilities for overnight sleep screening., ... saturation and pulse rate data, and can operate ... needs:, ,1. The Model 130 can retain ... single patient, making the device ideally suited for ...
... inserting a finger into comfortable holder, ... and continuous measurement is performed., ... height. In darker surroundings, back light ... ,Light weight, compact contour and ...
... or spot check pulse oximetry ... an internal rechargeable battery. ... modes make it ideal for ... clinical environment; during emergency air ...
Medicine Products: